| 新型口服抗凝药达比加群酯研究进展 |
| |
| 引用本文： | 肖宜超.新型口服抗凝药达比加群酯研究进展[J].心血管病学进展,2011,32(4):575-578. |
| |
| 作者姓名： | 肖宜超 |
| |
| 作者单位： | 中南大学湘雅二医院心血管内科,湖南,长沙,410011 |
| |
| 摘 要： | 达比加群酯是一种新型合成的直接凝血酶抑制剂,口服经胃肠吸收后,在体内转化为具有直接抗凝血活性的达比加群。现主要对达比加群酯的药理学、相关临床研究、临床应用前景进行综述。
|
| 关 键 词： | 抗凝药 达比加群酯 凝血酶抑制剂 心房颤动 静脉血栓栓塞 |
Research Progress in Novel Oral Anticoagulant:Dabigatran Etexilate |
| |
| XIAO Yi-chao.Research Progress in Novel Oral Anticoagulant:Dabigatran Etexilate[J].Advances in Cardiovascular Diseases,2011,32(4):575-578. |
| |
| Authors: | XIAO Yi-chao |
| |
| Institution: | XIAO Yi-chao,LIU Qi-ming (Department of Cardiology,The Second Xiangya Hospital of Central South University,Changsha 410011,Hunan,China) |
| |
| Abstract: | Dabigatran etexilate is the prodrug of dabigatran,a potent,nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.This review provides an overview of the pharmacology of dabigatran etexilate,and describes the most recent published data on clinical trials with the new oral anticoagulants. |
| |
| Keywords: | anticoagulant dabigatran etexilate direct thrombin inhibitor atrial fibrillation venous thromboembolism |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
